Skip to main content
OpenTrials

Clinical trial condition

Leukemia, Lymphocytic, Chronic, B-Cell

Explore clinical trials studying Leukemia, Lymphocytic, Chronic, B-Cell. Study availability and eligibility vary by location and protocol.

45 public trials 7 recruiting studies
Refine in advanced search Browse all conditions

Leukemia, Lymphocytic, Chronic, B-Cell trial results

Completed

A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia

NCT02733042

Conditions
Chronic Disease, Disease Attributes, Hematologic Diseases, +20 more
Locations
  • Banner MD Anderson Cancer Center Gilbert, Arizona, United States
  • Pinnacle Oncology Hematology Scottsdale, Arizona, United States
  • University of Colorado Cancer Center Aurora, Colorado, United States
  • Shands Cancer Center University of Florida Gainesville, Florida, United States
View all 66 locations
View Trial Details
Completed

Bendamustine Combined With Alemtuzumab in Pretreated Chronic Lymphocytic Leukemia (CLL)

NCT00951457

Conditions
Chronic Disease, Disease Attributes, Hematologic Diseases, +13 more
Locations
  • Medizinische Universitaet Innsbruck, Abtlg. f. Haematologie und Onkologie Innsbruck, Tyrol, Austria
  • Landeskrankenhaus Feldkirch Feldkirch, Austria
  • A.ö. Landeskrankenhaus Leoben Leoben, Austria
  • Krankenhaus der Elisabethinen Linz Linz, Austria
View Trial Details
Completed

A Study to Evaluate Ibrutinib Retention in Chronic Lymphocytic Leukemia Participants Treated in a Real World Setting

NCT03720561

Conditions
Chronic Disease, Disease Attributes, Hematologic Diseases, +13 more
Locations
  • Ospedali Riuniti Di Ancona Ancona, Italy
  • U.O.C. Ematologia e Terapia Cellulare Ospedale C e G Mazzoni Ascoli Piceno, Italy
  • U.O. Ematologia con Trapianto- AOU Policlinico di Bari Bari, Italy
  • U.O. Ematologia Istituto Tumori Giovanni Paolo II Bari, Italy
View all 39 locations
View Trial Details
Completed

Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi

NCT02639910

Conditions
Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +15 more
Locations
  • Clinical Study Site Jacksonville, Florida, United States
  • Clinical Study Site Rochester, Minnesota, United States
  • Clinical Study Site Columbus, Ohio, United States
  • Clinical Study Site Graz, Austria
View all 17 locations
View Trial Details
Completed

A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

NCT02406742

Conditions
Chronic Disease, Disease Attributes, Hematologic Diseases, +13 more
Locations
  • University of California San Diego La Jolla, California, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • Hackensack University Medical Center Hackensack, New Jersey, United States
  • Weill Cornell Medical College Dr. Feldman's Office New York, United States
View all 24 locations
View Trial Details
Completed

An Observational Study of MabThera Subcutaneous (SC) Safety in Participants With Non-Hodgkin's Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL)

NCT03289182

Conditions
Chronic Disease, Disease Attributes, Hematologic Diseases, +15 more
Locations
  • Soon Chun Hyang University Hospital Bucheon Bucheon-si, South Korea
  • Inje University Busan Paik Hospital Busan, South Korea
  • Pusan National University Hospital Busan, South Korea
  • Keimyung University Dongsan Medical Center Daegu, South Korea
View all 25 locations
View Trial Details
Completed

Intravenous BI 836826 in Combination With Ibrutinib in Relapsed/Refractory CLL Patients Who Have Been Pre-treated With at Least One Prior Line of Systemic Therapy, and Who Are Eligible for Treatment With Ibrutinib

NCT02759016

Conditions
Chronic Disease, Disease Attributes, Hematologic Diseases, +13 more
Locations
  • City of Hope Duarte, California, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Oregon Health and Sciences University Portland, Oregon, United States
View Trial Details

Related conditions